Dova Pharmaceuticals (DOVA) Reports In-Line Q4 EPS

Dova Pharmaceuticals (NASDAQ: DOVA) reported Q4 EPS of ($0.36), in-line with the analyst estimate of ($0.36).

For earnings history and earnings-related data on Dova Pharmaceuticals (DOVA) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown